GLP-1 Analogues

GLP-1 Analogues

GLP-1 (Glucagon-Like Peptide-1) receptors agonists are copies of the naturally occurring GLP-1 hormone that have been modified in some way to make it more effective in treatment. They have an important role in the treatment of type 2 diabetes and obesity as they stimulate the release of insulin, suppress glucagon, decelerate gastric emptying, and increase satiety. These drugs assist in glycemic control and allow for effective weight loss, the two effects being protective of the heart in diabetic patients.

The GLP-1 Analogues Market is expected to grow with a significant CAGR of 28% during the forecast period (2024-2032) due to type 2 diabetes and obesity have risen significantly over the recent past all over the world. Further, increasing the demand for weight loss solutions as well as expanding cardiovascular effectivity scope drive the market. The availability of new methods of drug delivery, especially including oral preparations and the development of long-acting analogues also increases the adoption of the drug. Furthermore, increased patient awareness levels and government promotion related to diabetes improve market access.

On June 12, 2023, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new findings for efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21-24.

• Based on the indication, the market is segmented into Dulaglutide (Trulicity), Exenatide (Bydureon, Byetta), Liraglutide (Victoza, Saxenda), Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound). The Liraglutide (Victoza, Saxenda) held a significant share of the market in 2023. Liraglutide is an area’s key driver of growth because it is a miscellaneous GLP-1 that is effective in the treatment of both type 2 diabetes and obesity with cardiovascular effects. The versatility of the product, which goes under the brand name Victoza for diabetes and Saxenda for obesity, means a wider market base. Moreover, companies concentrate on approaches to enlarging indications, enhancing marketing initiatives, and ensuring greater compliance through delivery systems. For instance, on June 24, 2024, Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States.
• Based on application, the market is segmented into type 2 diabetes and weight loss. Type 2 diabetes held a significant share of the market in 2023. The increasing global incidence of type 2 diabetes leads to the need for more GLP-1 analogues such as liraglutide that help to manage blood sugar levels while promoting weight loss. Such drugs are progressively preferred with respect to conventional treatments for their multiple valued aspects. Moreover, companies are improving access by expanding into growth lots and partnering with healthcare facilities exerting pressure for early detection.
• Based on the distribution channel, the market is segmented into hospitals, retail pharmacies, and online pharmacies. The retail pharmacies are expected to grow with a significant CAGR during the forecast period (2024-2032). Retail pharmacies have an important function in the probabilities of the distribution of GLP-1 analogues, focusing on accessibility and demand by users. Their coverage assists manufacturers in accessing the two markets, especially the urban and the rural areas, making the demand higher. It is required to establish ongoing relations with retail chains, raise awareness and provide training and support programs that would increase compliance with therapy regimens.
• For a better understanding of the market adoption of GLP-1 Analogues, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is because of a growing incidence of diabetes, the growth of cities, and, lastly, the increase in health care costs. Adding to this, the increased concerns among people regarding proper diabetes management drive the growth of superior diabetes management solutions in key areas such as China, India, and Japan. Moreover, companies pay much attention to growing the coverage through mergers, acquisitions, joint ventures, and own production facilities as well as localized advertisement techniques. More importantly, the approval of regulators and the availability of low-cost products are essential for new markets. Further, the concerned e-health technologies and telemedicine are helping the healthcare unit inpatient reach and compliance in rural areas.
• Some of the major players operating in the market include Novo Nordisk A/S, Lilly, Sanofi, AstraZeneca, Pfizer Inc., Boehringer Ingelheim International GmbH, Amgen Inc., ZEALAND PHARMA, Merck & Co., Inc., Hanmi Pharm.Co.,Ltd.